Tirzepatide Dosage: What the Recommended Schedule Actually Means for You

The real reason the schedule starts low

Newly starting tirzepatide at 2.5 mg can feel anticlimactic. The dose is there to let your gastrointestinal system acclimatise to the medicine, not to produce measurable weight loss. Nausea, reflux and loose stools are common in the first weeks, keeping the opening dose modest reduces how pronounced those effects are. Think of it as the body learning the medicine rather than the medicine doing its main job.

After roughly four weeks at 2.5 mg, most people move to 5 mg. That's where meaningful appetite reduction tends to become noticeable for the first time. The full Mounjaro overview explains how tirzepatide's dual GIP and GLP-1 receptor activation slows gastric emptying and increases feelings of fullness, effects that build as the dose rises.

Each subsequent step (7.5 mg, 10 mg, 12.5 mg, 15 mg) follows the same four-week minimum interval. There's no clinical benefit to rushing. The titration pace exists because the SURMOUNT trial programme, which enrolled thousands of adults with obesity, used these intervals to balance efficacy with tolerability; faster increases are associated with more GI side effects without improving outcomes. The NHS medicines information for tirzepatide covers the standard titration approach in detail.

What actually determines your maintenance dose

"Recommended dosage" implies a single destination. In practice, the Mounjaro recommended dosage is the highest dose you tolerate well and that your prescriber judges is achieving its clinical purpose. For some people that's 10 mg, and if you want to understand what reaching that point involves, the tirzepatide 10 mg dosage page covers what to expect at that stage. For others it's 15 mg. A small number find 7.5 mg is where they remain.

Several factors shape where someone ends up. Persistent side effects that don't settle are the most common reason a dose increase is deferred or reversed. Co-existing health conditions, other medicines being taken at the same time, and how weight-loss progress is tracking over months all feed into the conversation between a patient and their prescriber.

A useful practical note: if a dose increase happens to fall around a bank holiday or you're away when your next pen is due, timing can shift by a few days. That's a question worth raising with your prescribing team rather than guessing; the prescriber decides what adjustment, if any, is appropriate. The detail of what's in each dose format is covered on the tirzepatide dosage guide, including injection-site and storage notes.

NICE's appraisal of tirzepatide (TA1026) noted that if someone achieves less than 5% body-weight reduction after six months at the highest dose they can tolerate, continuing treatment should be reviewed. That threshold isn't a punishment, it's a built-in clinical checkpoint designed to make sure people are getting genuine benefit.

Side effects across the dose range and what to watch for

The GI side-effect profile of tirzepatide is well characterised. Nausea is the most reported, followed by diarrhoea, constipation, indigestion, burping and, less commonly, vomiting. These tend to peak in the first week or two after a dose increase, then settle. Moving slowly up the titration ladder is one of the reasons the schedule was designed the way it was.

There are symptoms that warrant prompt medical attention rather than watchful waiting. Severe abdominal pain (particularly pain that radiates toward the back and doesn't ease) should be assessed urgently, as the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, though infrequent, risk with GLP-1 medicines. Patients can report suspected side effects directly via the Yellow Card scheme.

Dose adjustments in response to side effects are standard practice, not a sign of failure. Your prescriber may hold the current dose for a further four weeks rather than increasing, or in some cases step back temporarily. Any of those decisions requires a clinical review, the dose schedule is a framework, not a rigid conveyor belt.

Information on the 5 mg dose specifically and the 15 mg maintenance dose is covered in more detail on their respective pages if you want to understand what each step involves.

Private access, NHS access, and what a clinical assessment covers

Tirzepatide is prescription-only. The only lawful route to it in the UK is a prescriber, whether through the NHS or a regulated private pharmacy. On the NHS, NICE's phased rollout (TA1026) means eligibility is currently tied to specific BMI thresholds and the number of weight-related conditions someone has; the criteria are tightening over time as more people become eligible. Many people find the NHS route involves waiting lists, and that private access is faster for those who meet the clinical criteria.

Privately, the licensed eligibility is adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine approval; a prescriber assesses the full clinical picture, medical history, other medicines, contraindications.

For context on what private treatment costs and what's included in a transparent price, the Mounjaro pricing page sets that out plainly. And if you're exploring whether this treatment is right for your situation, the weight-loss treatment overview covers the broader landscape. A prescriber at nume reviews every consultation the same day, a real clinician, reading your answers and making an individual decision about suitability and, if treatment proceeds, the appropriate starting point on the dose schedule.

Check your eligibility by starting a free consultation at our weight-loss treatments page.